Cirrhosis is staged in two main ways: by how much scar tissue has replaced healthy liver tissue (fibrosis scoring) and by how well the liver still functions (clinical staging). The most practical distinction is between compensated cirrhosis, where the liver is scarred but still working, and decompensated cirrhosis, where serious complications have developed. People with compensated cirrhosis have a median survival of over 12 years, while decompensated cirrhosis drops that to roughly 2 years.
Fibrosis Stages: F0 Through F4
Before cirrhosis develops, liver damage progresses through a grading system called the METAVIR scale, which pathologists use to describe how much scarring exists in the liver. The stages are:
- F0: No scarring at all.
- F1: Mild scarring, but the overall liver structure is mostly preserved.
- F2: Moderate scarring has begun forming within the liver.
- F3: Advanced scarring that covers larger areas and starts to interfere with blood flow through the organ.
- F4: Cirrhosis. Extensive scarring has caused lasting structural damage.
Stages F0 through F3 represent fibrosis, meaning the liver is accumulating scar tissue but hasn’t yet crossed into cirrhosis. F4 is where cirrhosis begins. Once you reach F4, doctors shift to clinical staging systems that measure how much function remains.
How Fibrosis Is Measured
A liver biopsy is the traditional way to assign a fibrosis score, but most people today are first assessed with a non-invasive imaging test called transient elastography (often known by the brand name FibroScan). This test sends a painless vibration through your abdomen and measures how stiff your liver tissue is, reported in kilopascals (kPa). Stiffer tissue means more scarring.
The kPa thresholds that indicate cirrhosis (F4) vary depending on the underlying cause of liver disease. For hepatitis C or fatty liver disease, a reading of 14 kPa or higher generally points to cirrhosis. For alcohol-related liver disease, the threshold is higher, at 19 kPa or above. Hepatitis B falls in between at roughly 12 kPa. These numbers are estimates, not hard cutoffs, and your doctor may follow up with additional testing if results are borderline.
Compensated Cirrhosis
Compensated cirrhosis is the earlier clinical stage. The liver is extensively scarred, but it’s still performing its essential jobs: filtering toxins, producing proteins, and processing bile. People at this stage have none of the major complications that define advanced disease, specifically no fluid buildup in the abdomen (ascites), no bleeding from swollen veins in the esophagus or stomach (variceal hemorrhage), no confusion or cognitive changes from toxin buildup (hepatic encephalopathy), and no jaundice.
This stage is often silent. Physical exams, blood tests, and imaging can all come back completely normal in someone with compensated cirrhosis. Some people develop subtle signs like small spider-shaped blood vessel clusters on the chest, back, or face (spider angiomata) or redness on the palms, but these aren’t reliable enough to diagnose the condition on their own. Many people discover they have cirrhosis only when tested for another reason.
Because symptoms are minimal or absent, compensated cirrhosis can persist for years. The median survival at this stage exceeds 12 years, and with treatment of the underlying cause (stopping alcohol use, treating hepatitis, managing metabolic disease), some people stabilize and never progress further.
Decompensated Cirrhosis
Decompensated cirrhosis is the turning point. It means the liver can no longer keep up with the body’s needs, and one or more serious complications have appeared. The transition from compensated to decompensated disease is the single most important milestone in cirrhosis, because it dramatically changes both quality of life and life expectancy.
The hallmark complications are:
- Ascites: Fluid accumulates in the abdomen, causing swelling, discomfort, and sometimes difficulty breathing. This is the most common first sign of decompensation.
- Variceal bleeding: Rising pressure in the vein that feeds the liver forces blood through smaller, fragile vessels in the esophagus and stomach. These swollen veins (varices) can rupture and cause life-threatening bleeding.
- Hepatic encephalopathy: The liver can no longer clear ammonia and other toxins from the blood, leading to confusion, personality changes, disorientation, and in severe cases, coma.
- Jaundice: Yellowing of the skin and eyes as the liver loses its ability to process bilirubin.
Once any one of these complications develops, you’ve crossed into decompensated cirrhosis. Median survival drops to about 2 years without a transplant, though individual outcomes vary widely depending on how well the complications respond to treatment.
The Child-Pugh Scoring System
The Child-Pugh score is the most widely used tool for grading how severely cirrhosis has impaired liver function. It combines five measurements: bilirubin levels in the blood, albumin (a protein the liver produces), how quickly your blood clots, whether ascites is present, and whether encephalopathy has developed. Each factor gets 1 to 3 points, and the total places you in one of three classes.
- Class A (5 to 6 points): The liver is still functioning well. One-year survival is essentially 100%, and two-year survival is around 85%.
- Class B (7 to 9 points): Moderate liver damage. One-year survival is about 80%, and two-year survival drops to 60%.
- Class C (10 to 15 points): Severe damage. One-year survival is roughly 45%, and only about 35% survive to two years.
Class A largely overlaps with compensated cirrhosis, while Classes B and C typically involve decompensated disease. This scoring system helps doctors decide on treatment intensity and whether to begin evaluating for a liver transplant.
The MELD Score and Transplant Priority
The MELD score serves a different purpose. Rather than classifying severity in broad categories, it estimates how urgently someone needs a liver transplant within the next three months. It uses a numerical scale from 6 (least ill) to 40 (gravely ill), calculated from blood tests measuring kidney function, clotting ability, and bilirubin levels.
The relationship between MELD score and 90-day mortality is steep:
- Below 9: 1.9% risk of death within 90 days
- 10 to 19: 6% risk
- 20 to 29: 19.6% risk
- 30 to 39: 52.6% risk
- Above 40: 71.3% risk
When organs become available, they go to the candidates with the highest MELD scores first. The exact score needed to receive a transplant varies by hospital and region. A common benchmark is that transplant centers set standard exception scores at about 3 points below their hospital’s median transplant score, so if the typical patient at a given center receives a liver with a score of 28, exceptions start around 25.
How Cirrhosis Progresses Over Time
Cirrhosis doesn’t follow a fixed timeline. Some people remain compensated for decades, especially if the underlying cause is addressed early. Others progress to decompensation within a few years, particularly if the damaging factor (alcohol, active hepatitis, ongoing obesity) continues unchecked.
The annual rate of transitioning from compensated to decompensated cirrhosis is roughly 5% to 7% per year, though this varies significantly based on the cause and whether it’s being treated. Rising pressure in the portal vein (the main vessel supplying the liver) is the driving force behind most complications. When that pressure crosses certain thresholds, the risk of varices forming and ascites developing climbs sharply.
Once decompensation occurs, it rarely reverses on its own. Treatment focuses on managing each complication individually: draining fluid, preventing bleeding, lowering ammonia levels. For people with advanced decompensated disease, liver transplantation is often the only option that changes the long-term trajectory. The good news is that outcomes after transplant are generally strong, with most recipients returning to normal or near-normal function.